Leerink raised the firm’s price target on Arcus Biosciences (RCUS) to $49 from $36 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Highlights Casdatifan Momentum in Call
- Arcus Biosciences reports Q4 EPS (89c), consensus ($1.08)
- Arcus Biosciences files automatic mixed securities shelf
- Buy Rating on Arcus Biosciences Driven by Best-in-Class Casdatifan Data in Renal Cell Carcinoma and Favorable Phase 3 Risk‑Reward
- Arcus’s Lead HIF-2α Inhibitor Delivers Superior Late-Line RCC Efficacy, De-Risking PEAK-1 and Supporting Buy Rating